Drug intelligence / Profile preview

C-KAD

Development stage: Unknown
Lead developer: Livionex
Modality: Small Molecules
Administration: Ophthalmic

Overview

C-KAD is a topical ophthalmic drug candidate developed by Livionex for the treatment of early to moderate-stage age-related cataracts. The drug is a proprietary formulation of the metal chelator ethylenediaminetetraacetic acid (EDTA), specifically designed to penetrate the lens of the eye. Its mechanism of action involves targeting and disrupting calcium-lipid-protein aggregates, which are a primary cause of lens clouding and cataract formation. By chelating the calcium ions that stabilize these aggregates, C-KAD aims to dissolve lens opacities and restore transparency, potentially offering a non-surgical therapeutic option for cataract patients. The program has completed Phase 2 clinical trials and is progressing toward Phase 3 development in consultation with the FDA.

Other names: C-KAD Eye Drops

Beyond the preview

Go deeper on C-KAD.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on C-KAD.

Explore the full profile